Home Print this page Email this page Small font size Default font size Increase font size
Users Online: 666
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 9  |  Issue : 8  |  Page : 4363-4367

Clinical profile of osteonecrosis in systemic lupus erythematosus – Experience from a tertiary care centre in South India


1 Department of Rheumatology, Sri Ramachandra Institute of Higher Education and Research; Department of Rheumatology, Madras Medical College and RGGGH, Chennai, Tamil Nadu, India
2 Department of Rheumatology, Madras Medical College and RGGGH, Chennai, Tamil Nadu; Department of Rheumatology, KIMS, Thiruvananthapuram, Kerala, India
3 Department of Rheumatology, Madras Medical College and RGGGH; Department of Rheumatology, Kilpauk Medical College, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Balaji Chilukuri
1/3B Sai Lakshmi Enclave, Patel Street, West Mambalam, Chennai - 600 033, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jfmpc.jfmpc_1234_19

Rights and Permissions

Introduction: Osteonecrosis or Avascular necrosis of bone (AVN) is a well recognized complication of systemic lupus erythematosus (SLE) leading to significant morbidity. Methods: We did a cross sectional descriptive study in cohort of SLE patients, on regular follow-up at our Rheumatology OPD over a period of 5 years from 2012 to 2017. Results: Of the total 415 SLE, 5.1% (n = 21) patients were diagnosed to have osteonecrosis. The mean age was 32.8 ± 7.6 years. Male: female were 1:4.2. Mean time interval between the onset of SLE and diagnosis of osteonecrosis was 4.1 ± 2.7 years. Pain (100%) was the most common presenting symptom followed by limping gait (42.8%). Most common site affected by osteonecrosis was femoral head (80.9%) (n = 17). 14.3% (n = 3) had multifocal involvement. The most common systemic involvement was musculoskeletal system (80.9%). In total 28.5% had secondary antiphospholipid syndrome. Mean SLEDAI-2K at the time of diagnosis of osteonecrosis was 5.3 ± 2.9. Hypertension 19%, hypothyroidism 9.5%, osteoporosis 24%, and chronic HCV infection 4.7% were the associated comorbidities. The most common stage by imaging at diagnosis was stage IV (38%), followed by 24% stage V, 19% stage III and 9.5% stage II and 9.5% stage VI. Medical management include bisphosphonates (100%), statins (90.4%) and anticoagulant therapy (28.5%), while 9.5% received core decompression surgery and 14.3% underwent total hip replacement. The mean daily dose of prednisolone at diagnosis of osteonecrosis was 8.5mg (range 5–20mg). Conclusion: This study described the prevalence and epidemiology of osteonecrosis in our cohort of SLE patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed75    
    Printed3    
    Emailed0    
    PDF Downloaded18    
    Comments [Add]    

Recommend this journal